HSD17B2: A Potential Drug Target and Biomarker for Human Diseases

Target Name: HSD17B2

NCBI ID: G3294

HSD17B2

HSD17B2: A Potential Drug Target and Biomarker for Human Diseases

HSD17B2, also known as human short chain dehydrogenase/reductase family 9C member 2, is a gene that encodes a protein involved in the metabolism of lipids. The HSD17B2 protein is a key enzyme in the fatty acid beta-oxidation pathway, which is a critical pathway for the production of energy from fatty acids in the body.

Mutations in the HSD17B2 gene have been linked to a variety of human diseases, including cardiovascular disease, obesity, and diabetes. The HSD17B2 protein has also been shown to play a role in the development and progression of certain types of cancer.

As a drug target, HSD17B2 has been identified as a potential target for a variety of drugs, including inhibitors of fatty acid beta-oxidation and HSD17B2 itself. One such drug, called JU-21245, has been shown to inhibit HSD17B2 activity and reduce the production of certain metabolites that have been linked to the development of certain types of cancer.

In addition to its potential as a drug target, HSD17B2 has also been shown to be a potential biomarker for a variety of diseases. For example, studies have shown that HSD17B2 activity can be used as a diagnostic marker for certain forms of cancer, such as colon cancer.

The HSD17B2 protein is also of interest to researchers studying the role of this gene in human disease. By studying the function of HSD17B2, researchers hope to gain a better understanding of how this gene contributes to the development and progression of certain diseases.

Overall, HSD17B2 is a gene that has the potential to be a drug target and a biomarker for a variety of diseases. Further research is needed to fully understand its role in human disease and to develop effective treatments.

Protein Name: Hydroxysteroid 17-beta Dehydrogenase 2

Functions: Catalyzes the NAD-dependent oxidation of the highly active 17beta-hydroxysteroids, such as estradiol (E2), testosterone (T), and dihydrotestosterone (DHT), to their less active forms and thus regulates the biological potency of these steroids. Oxidizes estradiol to estrone, testosterone to androstenedione, and dihydrotestosterone to 5alpha-androstan-3,17-dione. Also has 20-alpha-HSD activity

The "HSD17B2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HSD17B2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets